140 related articles for article (PubMed ID: 9598481)
1. Superficial bladder tumors and increased reactivity against mycobacterial antigens before bacillus Calmette-Guerin therapy.
Zlotta AR; Drowart A; Van Vooren JP; Shekarsarai H; De Cock M; Pirson M; Palfliet K; Jurion F; Simon J; Schulman CC; Huygen K
J Urol; 1998 Jun; 159(6):1885-91. PubMed ID: 9598481
[TBL] [Abstract][Full Text] [Related]
2. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
[TBL] [Abstract][Full Text] [Related]
3. Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guérin (BCG) in patients with superficial bladder cancer.
Zlotta AR; Drowart A; Huygen K; De Bruyn J; Shekarsarai H; Decock M; Pirson M; Jurion F; Palfliet K; Denis O; Mascart F; Simon J; Schulman CC; Van Vooren JP
Clin Exp Immunol; 1997 Jul; 109(1):157-65. PubMed ID: 9218839
[TBL] [Abstract][Full Text] [Related]
4. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary?
Zlotta AR; van Vooren JP; Huygen K; Drowart A; Decock M; Pirson M; Jurion F; Palfliet K; Denis O; Simon J; Schulman CC
Eur Urol; 2000 Apr; 37(4):470-7. PubMed ID: 10765079
[TBL] [Abstract][Full Text] [Related]
5. Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guérin.
van der Meijden AP; Steerenberg PA; van Hoogstraaten IM; Kerckhaert JA; Schreinemachers LM; Harthoorn-Lasthuizen EJ; Hagenaars AM; de Jong WH; Debruijne FM; Ruitenberg EJ
Cancer Immunol Immunother; 1989; 28(4):287-95. PubMed ID: 2784716
[TBL] [Abstract][Full Text] [Related]
6. Evolution of cellular and humoral response against Tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer.
Zlotta A; Drowart A; van Vooren JP; Simon J; Schulman CC; Huygen K
Acta Urol Belg; 1994 Sep; 62(3):63-8. PubMed ID: 7976857
[TBL] [Abstract][Full Text] [Related]
7. Reactive antibodies against bacillus Calmette-Guerin heat-shock protein-65 potentially predict the outcome of immunotherapy for high-grade transitional cell carcinoma of the bladder.
Ardelt PU; Kneitz B; Adam P; Reiss C; Kocot A; Fensterle J; Chen L; Pasqualini R; Arap W; Gerharz EW; Riedmiller H
Cancer; 2010 Feb; 116(3):600-9. PubMed ID: 19957324
[TBL] [Abstract][Full Text] [Related]
8. Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review.
Patard JJ; Saint F; Velotti F; Abbou CC; Chopin DK
Urol Res; 1998; 26(3):155-9. PubMed ID: 9694595
[TBL] [Abstract][Full Text] [Related]
9. Long term protection in bladder cancer following intralesional immunotherapy.
Reichert DF; Lamm DL
J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
[TBL] [Abstract][Full Text] [Related]
10. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
11. Reactive arthritis associated with bacillus Calmette-Guérin immunotherapy for carcinoma of the bladder: immune reactivity against mycobacterial antigens.
Miossec P
J Rheumatol; 1996 Aug; 23(8):1485. PubMed ID: 8856640
[No Abstract] [Full Text] [Related]
12. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.
Morales A; Eidinger D; Bruce AW
J Urol; 1976 Aug; 116(2):180-3. PubMed ID: 820877
[TBL] [Abstract][Full Text] [Related]
13. Peripheral blood lymphocyte response in patients with superficial transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guérin--a useful marker of response?
Schmidt AC; Bouic PJ; Heyns CF; De Kock ML
Br J Urol; 1993 Feb; 71(2):179-82. PubMed ID: 8461951
[TBL] [Abstract][Full Text] [Related]
14. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
Yutkin V; Pode D; Pikarsky E; Mandelboim O
J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
[TBL] [Abstract][Full Text] [Related]
15. Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors.
Lüftenegger W; Ackermann DK; Futterlieb A; Kraft R; Minder CE; Nadelhaft P; Studer UE
J Urol; 1996 Feb; 155(2):483-7. PubMed ID: 8558641
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of action of bacillus Calmette-Guérin in the treatment of superficial bladder cancer.
Patard JJ; Chopin DK; Boccon-Gibod L
World J Urol; 1993; 11(3):165-8. PubMed ID: 8401636
[TBL] [Abstract][Full Text] [Related]
17. Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder.
Nunez-Nateras R; Castle EP; Protheroe CA; Stanton ML; Ocal TI; Ferrigni EN; Ochkur SI; Jacobsen EA; Hou YX; Andrews PE; Colby TV; Lee NA; Lee JJ
Urol Oncol; 2014 Jan; 32(1):45.e23-30. PubMed ID: 24055426
[TBL] [Abstract][Full Text] [Related]
18. Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall.
Böhle A; Gerdes J; Ulmer AJ; Hofstetter AG; Flad HD
J Urol; 1990 Jul; 144(1):53-8. PubMed ID: 2359181
[TBL] [Abstract][Full Text] [Related]
19. Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview.
Witjes JA; vd Meijden AP; Debruyne FM
Urol Int; 1990; 45(3):129-36. PubMed ID: 2190404
[TBL] [Abstract][Full Text] [Related]
20. Purified Protein Derivative Skin test prior to bacillus Calmette-Guérin Therapy May have Therapeutic Impact in Patients with Nonmuscle Invasive Bladder Cancer.
Niwa N; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Oya M
J Urol; 2018 Jun; 199(6):1446-1451. PubMed ID: 29307686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]